BlackRock
ANTX icon

BlackRock’s AN2 Therapeutics ANTX Stock Holding History

BlackRock’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.06M Buy
1,665,494
+1,346,726
+422% +$5.79M ﹤0.01% 3770
2026
Q1 		$1.09M Sell
318,768
-4,567
-1% -$9.43K ﹤0.01% 4316
2025
Q4 		$369K Buy
323,335
+2,424
+0.8% +$2.83K ﹤0.01% 4567
2025
Q3 		$408K Buy
320,911
+1,616
+0.5% +$1.85K ﹤0.01% 4506
2025
Q2 		$338K Buy
319,295
+18,609
+6% +$22.2K ﹤0.01% 4533
2025
Q1 		$409K Sell
300,686
-735
-0.2% -$925 ﹤0.01% 4449
2024
Q4 		$416K Buy
301,421
+245
+0.1% +$297 ﹤0.01% 4458
2024
Q3 		$322K Buy
301,176
+1,473
+0.5% +$2.56K ﹤0.01% 4427
2024
Q2 		$644K Buy
299,703
+8,617
+3% +$20.5K ﹤0.01% 4280
2024
Q1 		$946K Sell
291,086
-14,755
-5% -$161K ﹤0.01% 4210
2023
Q4 		$6.27M Buy
305,841
+263,679
+625% +$4.41M ﹤0.01% 3601
2023
Q3 		$678K Buy
42,162
+18,680
+80% +$212K ﹤0.01% 4340
2023
Q2 		$200K Sell
23,482
-459,947
-95% -$3.31M ﹤0.01% 4735
2023
Q1 		$4.77M Buy
483,429
+38,220
+9% +$425K ﹤0.01% 3653
2022
Q4 		$4.24M Buy
445,209
+256,924
+136% +$3.44M ﹤0.01% 3799
2022
Q3 		$3.27M Buy
188,285
+1,175
+0.6% +$13.7K ﹤0.01% 3942
2022
Q2 		$1.45M Buy
+187,110
New +$2.48M ﹤0.01% 4385

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock's ANTX Position: Q2 2026 in Review

BlackRock increased its AN2 Therapeutics (ANTX) stake by 422% in Q2 2026, buying an estimated $5.79M and bringing the position to 1,665,494 shares worth $8.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

BlackRock first reported a position in ANTX in Q2 2022 and has held it in 17 quarters since. 59 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • BlackRock held 1,665,494 shares of AN2 Therapeutics worth $8.06M as of Q2 2026.
  • BlackRock bought 1,346,726 AN2 Therapeutics shares in Q2 2026, an estimated $5.79M.
  • AN2 Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3770 holding.
  • BlackRock first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 59 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.